A PROSPECTIVE, OBSERVATIONAL STUDY OF ADVERSE EFFECTS AND CLINICAL OUTCOMES OF TICAGRELOR.
Nisma Siddiqi
, Madiha Naaz , Amini Raunaq Fatima , A. Srinivas Rao , A.V.Kishore Babu
cyclopentyltriazolopyrimidines, acute coronary syndrome, antiplatelet, Naranjo’s casualty assessment scale, NSTEMI.
Even after the advancement in treatment of Acute Coronary Syndrome, it remains life-threatening. The standard therapy for treatment of ACS is dual antiplatelet therapy which includes combination of P2Y12 receptor antagonist along with aspirin. Ticagrelor is a drug which is a P2Y12 receptor antagonist belonging to the class cyclopentyltriazolopyrimidines.The study was conducted in AIG Hospitals, Gachibowli for a period of 6 months. A total of 85 patients of different age groups were considered. Out of 85 patients, 70 (82%) were found to be males and 15 (18%) was found to be females. The patients with age group ranging from 46-60 years which is late middle aged in both males and females were suffering from ACS. It has been shown that 35 males among 70 and 6 females among 15 were in the age group of 46-60 years to whom ticagrelor was prescribed after the stent was placed. Among 85 patients only 21.1% patients showed obesity. Among 85 patients 54 patients had hypertension, 45 patients had diabetes mellitus. Around 11% ,7% , and 3.5% patients showed dyspnea, bleeding and bradycardia respectively, these adverse effects were assessed using Naranjo’s casualty assessment scale. Drug discontinuation was also seen in 6 patients because of the adverse effects. Around 6% patients were re-hospitalized while on the drug Ticagrelor. From this study, it was concluded that maximum number of patients suffering from ACS are males, in the age group of 46-60 yrs. NSTEMI contributes maximum number of cases among the total cases. ADR’s were seen in 17 patients which were related with increased concentration of endogenous adenosine. Though the drug was discontinued in 3 patients because of severe dyspnea. Bleeding was reported in very few cases out of which 1 patient showed severe epistaxis and 2 patients showed severe brown spots; as a result, the drug was discontinued. Maximum number of ADR’s where seen in male patients and patients with co-morbidities. Re-hospitalization was seen in 5 patients during our study.
"A PROSPECTIVE, OBSERVATIONAL STUDY OF ADVERSE EFFECTS AND CLINICAL OUTCOMES OF TICAGRELOR. ", IJSDR - International Journal of Scientific Development and Research (www.IJSDR.org), ISSN:2455-2631, Vol.8, Issue 3, page no.1058 - 1067, March-2023, Available :https://ijsdr.org/papers/IJSDR2303174.pdf
Volume 8
Issue 3,
March-2023
Pages : 1058 - 1067
Paper Reg. ID: IJSDR_204416
Published Paper Id: IJSDR2303174
Downloads: 000347240
Research Area: Pharmacy
Country: hyderabad, telangana, India
ISSN: 2455-2631 | IMPACT FACTOR: 9.15 Calculated By Google Scholar | ESTD YEAR: 2016
An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 9.15 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator
Publisher: IJSDR(IJ Publication) Janvi Wave
